Rapid-Fire Roundtable on Melanoma: Focus on Advances in Adjuvant Treatment, Neoadjuvant Treatment, and Management of Metastatic Disease

Released On
December 22, 2021

Expires On
December 21, 2022

Media Type
Internet

Completion Time
45 minutes

Specialty
Hematology-Oncology

Topic(s)
Oncology

Scroll to the Bottom of this Information to Begin this Course

This continuing medical education activity is provided by

This activity is supported by an educational grant from Merck & Co., Inc.

Credit Available

  • Physicians — maximum of 0.75 AMA PRA Category 1 Credit(s)

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

The intended audience for this activity is oncologists and other health care professionals involved in the management of patients with advanced melanoma.

Program Overview

Treatment for patients with advanced melanoma has been revolutionized through the integration of immune checkpoint inhibitors (CPI) and targeted therapy into management algorithms. With these advances, new challenges have emerged, including identifying the patients who will benefit most from adjuvant and neoadjuvant approaches. In this Rapid-Fire Roundtable educational activity, experts in the field discuss clinical advances pertaining to CPI-based therapy—evaluating patient and tumor characteristics that may inform treatment selection. Faculty will engage in a fast-paced review of the latest data on adjuvant and neoadjuvant regimens as well as emerging options for recurrent melanoma, providing key pearls on immunotherapy to guide clinical decision-making.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Review the latest evidence regarding the use of neoadjuvant treatment for patients with melanoma and the implications for clinical decision-making.
  • Evaluate patient and tumor characteristics that may help identify patients who may benefit from CPI-based adjuvant therapy based on the latest clinical evidence.
  • Examine the patient, tumor, and/or treatment characteristics that may help guide clinical decision-making for patients with recurrent melanoma.

Activity Chair

FACULTY_NAME

Jeffrey S. Weber, MD, PhD

Deputy Director
Laura and Isaac Perlmutter Cancer Center
Professor of Medicine
NYU Langone Medical Center
New York, NY

Faculty

FACULTY_NAME

Tara C. Mitchell, MD

Associate Professor of Medicine
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA

FACULTY_NAME

Hussein A. Tawbi, MD, PhD

Professor
MD Anderson Cancer Center
Houston, TX

Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP

Physician Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Conflicts of Interest

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control.

Activity Chair and Faculty report the following relevant financial relationship(s):

Tara C. Mitchell, MD
  • Advisor: Bristol-Myers Squibb, Merck, OncoSec
  • Independent Research Contractor (paid to institution): Bristol-Myers Squibb, Incyte, Merck
  • Hussein A. Tawbi, MD, PhD
  • Consultant: Boxer Capital, Bristol-Myers Squibb, Eisai, Genentech, Iovance, Karyopharm, Merck, Novartis, Pfizer
  • Independent Research Contractor: Bristol-Myers Squibb, Genentech, GlaxoSmithKline, Merck, Novartis
  • Jeffrey S. Weber, MD, PhD
  • Royalties or Patent Beneficiary Details: Moffitt Cancer Center
  • Advisor: Biond, CytomX, ImCheck, Incyte, Instil Bio, OncoC4, Sellas
  • Consultant: AstraZeneca, Biond, Bristol-Myers Squibb, Celldex, EMD Serono, Evaxion, Genentech, GlaxoSmithKline, ImCheck, Incyte, Merck, Nektar, Novartis, Sellas
  • Individual Stocks and Stock Options: Biond, Instil Bio, Neximmune, OncoC4
  • Reviewer reports the following relevant financial relationship(s):

    Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
  • No relevant financial relationships to disclose.
  • Vindico Medical Education Staff report the following relevant financial relationship(s):
  • No relevant financial relationships to disclose.
  • Instructions for Participation and Credit

    There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.

    Course Viewing Requirements

    Supported Browsers:
    Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
    Google Chrome 28.0+ for Windows, Mac OS, or Linux
    Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
    Safari 6.0+ for Mac OSX 10.7 and above

    Supported Phones & Tablets:
    Android 4.0.3 and above
    iPhone/iPad with iOS 6.1 or above

    Unlabeled and Investigational Usage

    The audience is advised that this continuing education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage.

    Copyright Statement

    Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the FDA. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

    Contact Information

    For CME questions please contact: CME@VindicoCME.com